Michael Golembiewski - Nov 30, 2023 Form 4 Insider Report for SEELOS THERAPEUTICS, INC. (SEEL)

Role: Chief Financial Officer
Signature: /s/ Michael Golembiewski
Stock symbol: SEEL
Transactions as of: Nov 30, 2023
Transactions value $: $100,223
Form type: 4
Date filed: 12/1/2023, 04:16 PM
Previous filing: Sep 1, 2023
Next filing: Jan 17, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SEEL	Common Stock	Purchase	$100K	+83K	+2405.8%	$1.21^*	86.5K	Nov 30, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $1.07 per share to $1.27 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.
F2	Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.

Content

The price reported in Column 4 is a weighted average purchase price. These shares were acquired in multiple open market transactions at prices ranging from $1.07 per share to $1.27 per share, inclusive. The Reporting Person undertakes to provide to the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares acquired at each separate price.

Effective on November 28, 2023, the Issuer conducted a reverse stock split at a ratio of 1-for-30 (the "Reverse Split"). The number of shares reported herein reflects the number of shares after the Reverse Split.